Literature DB >> 14528278

Ocular neovascularization: a valuable model system.

Peter Anthony Campochiaro1, Sean Francis Hackett.   

Abstract

There is no unique formula for angiogenesis. Instead there is a large group of potential participating proteins that interact in complex ways. Depending upon the surrounding cell types and the relative expression levels of angiogenesis-related proteins, the 'angiogenesis cascade' can vary. Therefore, it is valuable to study and compare the role of proteins in several well-characterized vascular beds. The eye provides a useful model system, because it contains several vascular beds sandwiched between avascular tissue. This allows for unequivocal identification and quantitation of new vessels. Retina-specific promoters combined with inducible promoter systems provide a means to regulate the expression of proteins of interest. As a relatively isolated compartment, the eye also provides advantages for gene transfer. By gaining insight regarding the molecular signals involved in various types of ocular angiogenesis, general concepts can emerge that may apply to other settings, including tumor angiogenesis. One concept that has emerged is that despite participation of multiple stimulatory factors for ocular neovascularization, VEGF plays an essential role and interruption of VEGF signaling is an important therapeutic strategy. Another concept is that while most studies have focused on prevention of ocular neovascularization, regression of new vessels is desirable and is achievable with at least three agents, combretastatin A-4 phosphate, pigment epithelium-derived factor, and angiopoietin-2. Finally, endostatin and angiostatin, which have been sources of controversy because of inconsistent results in tumor models, have been shown to have good efficacy when delivered by gene transfer in models of ocular neovascularization. These results provide leads for new ocular treatments and perspective for evaluation of studies of neovascularization in extraocular tissues.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14528278     DOI: 10.1038/sj.onc.1206773

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  22 in total

1.  Vascular endothelial growth factor and age-related macular degeneration: from basic science to therapy.

Authors:  Napoleone Ferrara
Journal:  Nat Med       Date:  2010-10       Impact factor: 53.440

2.  EphrinB reverse signaling contributes to endothelial and mural cell assembly into vascular structures.

Authors:  Ombretta Salvucci; Dragan Maric; Matina Economopoulou; Shuhei Sakakibara; Simone Merlin; Antonia Follenzi; Giovanna Tosato
Journal:  Blood       Date:  2009-05-01       Impact factor: 22.113

3.  A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t.

Authors:  Ling Zhang; Xi Shen; Qing Lu; Qingwei Zhou; Jiaqi Gu; Renbao Gan; Hui Zhang; Xiaodong Sun; Bing Xie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-09-01       Impact factor: 3.117

4.  Development of an experimental model of proliferative retinopathy by intravitreal injection of VEGF165.

Authors:  Emmerson Badaro; Eduardo Amorim Novais; Kalil Abdala; Mikael Chun; Muller Urias; Paulo Augusto de Arruda Melo Filho; Michel Eid Farah; Eduardo Buchele Rodrigues
Journal:  J Ocul Pharmacol Ther       Date:  2014-07-16       Impact factor: 2.671

5.  Rapid remodeling of airway vascular architecture at birth.

Authors:  Amy Ni; Erin Lashnits; Li-Chin Yao; Peter Baluk; Donald M McDonald
Journal:  Dev Dyn       Date:  2010-09       Impact factor: 3.780

6.  Inhibition of pathologic retinal neovascularization by alpha-defensins.

Authors:  Matina Economopoulou; Khalil Bdeir; Douglas B Cines; Franz Fogt; Yasmina Bdeir; Jacek Lubkowski; Wuyuan Lu; Klaus T Preissner; Hans-Peter Hammes; Triantafyllos Chavakis
Journal:  Blood       Date:  2005-08-25       Impact factor: 22.113

7.  Semaphorin 6A regulates angiogenesis by modulating VEGF signaling.

Authors:  Marta Segarra; Hidetaka Ohnuki; Dragan Maric; Ombretta Salvucci; Xu Hou; Anil Kumar; Xuri Li; Giovanna Tosato
Journal:  Blood       Date:  2012-09-24       Impact factor: 22.113

8.  Implantable tissue isolation chambers for analyzing tumor dynamics in vivo.

Authors:  Gabriel Gruionu; Despina Bazou; Nir Maimon; Mara Onita-Lenco; Lucian G Gruionu; Peigen Huang; Lance L Munn
Journal:  Lab Chip       Date:  2016-04-29       Impact factor: 6.799

9.  Histone H2AX is integral to hypoxia-driven neovascularization.

Authors:  Matina Economopoulou; Harald F Langer; Arkady Celeste; Valeria V Orlova; Eun Young Choi; Mingchao Ma; Athanassios Vassilopoulos; Elsa Callen; Chuxia Deng; Craig H Bassing; Manfred Boehm; Andre Nussenzweig; Triantafyllos Chavakis
Journal:  Nat Med       Date:  2009-04-19       Impact factor: 53.440

10.  Angiogenesis is not impaired in connective tissue growth factor (CTGF) knock-out mice.

Authors:  Esther J Kuiper; Peggy Roestenberg; Christoph Ehlken; Vincent Lambert; Henny Bloys van Treslong-de Groot; Karen M Lyons; Hans-Jürgen T Agostini; Jean-Marie Rakic; Ingeborg Klaassen; Cornelis J F Van Noorden; Roel Goldschmeding; Reinier O Schlingemann
Journal:  J Histochem Cytochem       Date:  2007-07-11       Impact factor: 2.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.